Know Cancer

forgot password

A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 2
18 Years
Not Enrolling
Peripheral T-cell Lymphoma

Thank you

Trial Information

A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

This is a Phase 2, single arm, non-randomized, open-label, multi-center study designed to
evaluate the safety and effectiveness of pralatrexate when administered with vitamin B12 and
folic acid supplementation to patients with relapsed or refractory PTCL.

Pralatrexate will be given over 3-5 minutes intravenously (IV), which means through a vein.
If pralatrexate is tolerated well, the patient will receive IV injections of pralatrexate
every week for 6 weeks, followed by 1 week without receiving pralatrexate. These 7 week
cycles will be repeated depending on response and tolerability.

Inclusion Criteria:

- Histologically/cytologically confirmed PTCL, using the Revised European American
Lymphoma (REAL) World Health Organization (WHO) disease classification:

1. T/Natural Killer (T/NK) cell leukemia/lymphoma

2. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)

3. Angioimmunoblastic T cell lymphoma

4. Blastic Natural Killer (NK) lymphoma (with skin, lymph node, or visceral

5. Anaplastic large cell lymphoma, primary systemic type

6. PTCL - unspecified

7. T/NK-cell lymphoma - nasal

8. Enteropathy-type intestinal lymphoma

9. Hepatosplenic T cell lymphoma

10. Extranodal peripheral T/NK-cell lymphoma - unspecified

11. Subcutaneous panniculitis T-cell lymphoma

12. Transformed mycosis fungoides

- Documented progression of disease after at least 1 prior treatment. Patients may not
have received experimental therapy as their only prior therapy. Patient has at least
1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis
of PTCL. Patient has recovered from the toxic effects of prior therapy. Patients
treated with monoclonal antibody therapy may be enrolled regardless of the time frame
of the therapy if they have progression of disease.

- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.

- ≥ 18 years of age.

- Adequate hematological, hepatic, and renal function.

- Women of childbearing potential must agree to practice a medically acceptable
contraceptive regimen from study treatment initiation until at least 30 days after
the last administration of pralatrexate and must have a negative serum pregnancy test
within 14 days prior to the first day of study treatment. Patients who are
postmenopausal for at least 1 year or are surgically sterilized do not require this

- Men who are not surgically sterile must agree to practice a medically acceptable
contraceptive regimen from study treatment initiation until at least 90 days after
the last administration of pralatrexate.

- Patient has given written informed consent.

Exclusion Criteria:

- Patient has:

1. Precursor T/NK neoplasms, with the exception of blastic NK lymphoma

2. T cell prolymphocytic leukemia (T-PLL)

3. T cell large granular lymphocytic leukemia

4. Mycosis fungoides, other than transformed mycosis fungoides

5. Sézary syndrome

6. Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and
lymphomatoid papulosis

- Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of
the cervix). If there is a history of prior malignancy, the patient must be disease
free for greater than or equal to 5 years.

- Congestive heart failure Class III/IV according to the New York Heart Association's
Heart Failure Guidelines.

- Uncontrolled hypertension.

- Human immunodeficiency virus (HIV)-positive diagnosis and is receiving combination
anti-retroviral therapy.

- Patient has, or history of, brain metastases or central nervous system (CNS) disease.

- Patient has undergone an allogeneic stem cell transplant.

- Patient has relapsed less than 75 days from time of an autologous stem cell

- Active uncontrolled infection, underlying medical condition including unstable
cardiac disease, or other serious illness that would impair the ability of the
patient to receive protocol treatment.

- Major surgery within 2 weeks of study entry.

- Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6
weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during
the course of the study.

- Receipt of corticosteroids within 7 days of study treatment, unless patient has been
taking a continuous dose of no more than 10 mg/day of prednisone for at least 1

- Use of any investigational drugs, biologics, or devices within 4 weeks prior to study
treatment or planned use during the course of the study.

- Previous exposure to pralatrexate.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response Rate Per Independent Central Review

Outcome Description:

Patient response to treatment was determined by independent central review using International Workshop Criteria (IWC). Results present the best overall response. The initial response assessment was scheduled at week 7 (prior to Cycle 2) and then prior to every even-numbered cycle (every 14 weeks) for up to two years after first dose.

Outcome Time Frame:

Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose

Safety Issue:


Principal Investigator

Owen O'Connor, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Columbia University


United States: Food and Drug Administration

Study ID:




Start Date:

August 2006

Completion Date:

February 2012

Related Keywords:

  • Peripheral T-cell Lymphoma
  • Peripheral T-cell Lymphoma
  • T-cell Lymphoma
  • Lymphoma
  • PDX
  • Pralatrexate
  • Vitamin B12
  • Folic acid
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral



Fred Hutchinson Cancer Research Center Seattle, Washington  98109
Memorial Sloan-Kettering Cancer Center New York, New York  10021
University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
Washington University School of Medicine Saint Louis, Missouri  63110
University of Rochester Cancer Center Rochester, New York  14642
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Dana-Farber Cancer Institute Boston, Massachusetts  02115
City of Hope National Medical Center Los Angeles, California  91010
Tulane Cancer Center New Orleans, Louisiana  70112
Emory University Atlanta, Georgia  30322
UT MD Anderson Cancer Center Houston, Texas  77030
New York Presbyterian Hospital New York, New York  10021
Yale University School Of Medicine New Haven, Connecticut  06520
Nevada Cancer Institute Las Vegas, Nevada  89135
Columbia University Medical Center New York, New York  10032
The Cancer Center at Hackensack University Medical Center Hackensack, New Jersey  07601
University of California at Los Angeles Los Angeles, California  90095
University of Chicago Hospital Chicago, Illinois  60637-1470